Most Read Articles
29 Nov 2017
Rapid onset opioids may allow for more effective treatment of breakthrough cancer pain as their pharmacokinetic profile closely mimics the pain’s time course
Stephen Padilla, 24 Oct 2017
Cancer drugs approved by the European Medicines Agency (EMA) from 2009 to 2013 have been sold in the market even without evidence of benefit on survival or quality of life (QoL), according to a study. Survival gains over existing treatment options or placebo, if any, are usually marginal.
Christina Lau, 22 Oct 2015
A 21-gene expression assay can identify patients with early-stage breast cancer who can skip adjuvant chemotherapy without facing an increased risk of recurrence at 5 years.
Dr Joslyn Ngu, 23 Nov 2017
Highlights from the Joint Cancer Genetics Meeting and the 15th International Meeting on the Psychosocial Aspects of Hereditary Cancer (IMPAHC) 2017

Psoriasis may elevate risk of melanoma, haematologic cancers

10 Apr 2017

There appears to be an increased risk of melanoma and haematologic cancers in patients with psoriasis compared with the general population, according to a recent study. This risk is not increased by systemic or biologic psoriasis treatments.

To examine the risk of melanoma and haematologic cancers in patients with psoriasis, as well as the association with various therapies, researchers used case-control and retrospective cohort designs. Fisher exact test was used to assess the risk with different types of therapies.

Patients with psoriasis were found to have 1.53 times higher risk of developing malignancy compared with patients without psoriasis (p<0.01). No significant differences were found in malignancy risk among those treated with topicals, phototherapy, systemics or biologic agents.

Furthermore, patients with psoriasis and malignancy did not have significantly worse survival that those without psoriasis, said researchers.

“It is possible that patients developed malignancy subsequent to the follow-up time included in the study,” they added.

A 2009 study found that many of the treatments for moderate to severe psoriasis, such as psoralen and ultraviolet A, traditional systemic therapies, and some biologic therapies, could elevate the risk of malignancy. It added that appropriate patient counselling and selection, as well as clinical follow-up, are warranted to maximize safety with such agents. [J Am Acad Dermatol 2009;60:1001-17]

On the other hand, a study by Christophers and colleagues concluded that more patients given biologic therapies improved from severe to moderate or mild psoriasis than those on other treatments. They added that more patients with plaque psoriasis and their dermatologists were satisfied with biologics than any other treatment. [J Dermatolog Treat 2013;24:193-8]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
29 Nov 2017
Rapid onset opioids may allow for more effective treatment of breakthrough cancer pain as their pharmacokinetic profile closely mimics the pain’s time course
Stephen Padilla, 24 Oct 2017
Cancer drugs approved by the European Medicines Agency (EMA) from 2009 to 2013 have been sold in the market even without evidence of benefit on survival or quality of life (QoL), according to a study. Survival gains over existing treatment options or placebo, if any, are usually marginal.
Christina Lau, 22 Oct 2015
A 21-gene expression assay can identify patients with early-stage breast cancer who can skip adjuvant chemotherapy without facing an increased risk of recurrence at 5 years.
Dr Joslyn Ngu, 23 Nov 2017
Highlights from the Joint Cancer Genetics Meeting and the 15th International Meeting on the Psychosocial Aspects of Hereditary Cancer (IMPAHC) 2017